Park Vale Capital

Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.

Dearman Ltd. specializes in clean cold and power technologies that utilize liquid air-powered engines. The company's primary innovation is the Dearman engine, a piston engine that operates on the expansion of liquid nitrogen or liquid air, providing zero-emission power and cooling solutions. This technology is applied in various sectors, including refrigerated transport for food and medicine, backup power and cooling for buildings, and urban vehicles such as city buses. Founded in 2011 and headquartered in London, Dearman aims to deliver significant reductions in operating costs, fuel consumption, and emissions through its proprietary technologies. The company is recognized for its commitment to innovation and engineering excellence, striving to contribute to a cleaner and more sustainable environment.

Causemo Inc. develops a fundraising and donor segmentation software as a service (SaaS) platform. It offers Causemo Insights, which uses data science and helps in raising funds for nonprofit organizations. The company was incorporated in 2013 and is based in Framingham, Massachusetts. Causemo Inc. operates as a subsidiary of The Pursuant Group, Inc.